Noida,
Uttar pardesh,
India
(PRBD.net)
11/29/2011 12:00:00 AM
-
In 2020, Roche, the world's largest biotech company and global investor in R&D is expected to lose US sales worth $2.5 billion as a result of biosimilar competition. IMARC Group, one of the world’s leading research and advisory firms, in its new report “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” finds that five of the Roche’s blockbuster biologicals (Avastin, Herceptin, Mabthera, Lucentis and Xolair) face biosimilar competition during 2011-2020. Projections from the report that are based on an extensive primary and secondary research suggest that the combined sales of these five drugs will decline from $10.7 billion in 2010 to $8.2 billion in 2020.
Despite this significant decline, Roche is still expected to be much better off than some of its other peers such as Amgen - atleast in the short term. Findings from the study suggest the excluding Mabthera, the company’s other four brands will face biosimilar competition only during 2019-2020. As a result, Roche will suffer most of its brand erosion post-2020. The study finds that unlike Roche, Amgen is expected to witness biosimilar competition in all four of its brands (Enbrel, Epogen, Neupogen, and Neulasta) during 2013-2015. Projections From the report suggest that the combined sales of these four products will reduce from $10.6 billion in 2010 to just $1.4 billion in 2020.
IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.
Key Aspects Analyzed:
Evaluating the Current Market Landscape of Biosimilars:
• Identification of currently marketed biosimilars and their historical performance
• Identifying the reasons for the slow uptake of currently marketed biosimilars
• Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilars
Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:
• Analyzing historical time series data on price, volume and sales erosion in the US & Europe
• Analyzing previous models and assumptions on price and volume erosion caused by biosimilars
• Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics
• Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classes
Evaluating the Market Potential of Biosimilars Across Various Molecules:
Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).
Focus of the Analysis for Each Molecule:
• Historical background and overview
• Historical brand sales
• Patent position
• Competing products
• Biosimilars in pipeline
• Brand and biosimilar sales forecasts
Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency
Focus of the Analysis for Each Indication:
• Historical brand sales
• Brand and biosimilar sales forecasts
• Indication wise breakup of molecules
Evaluating the Biosimilar Competitive Landscape:
• Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars
• Identifying biosimilar manufacturers and their pipelines
Understanding the Current Legislation on Biosimilars:
• An insight into the Biologics Price Competition and Innovation Act
• An insight into the key biosimilar issues that still remain unaddressed
• Interchangeability and Substitutability
• Data Exclusivity
• Statutory provisions for dealing with patent litigations
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-425-6531
IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145
To know more please visit: http://www.imarcgroup.com/
|
|
|
|
Contact Information
|
Get your Press release distributed to 90+ PR directories and 100’s of Journalists.
FREE featured news at PRBD.NET, PR4links.com and Sardnews.org worth $27.
|
|
|
|